Related Experiment Video
Updated: Jan 7, 2026

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease
Published on: September 22, 2023
Parabacteroides goldsteinii mitigates parkinsonism in LRRK2 mutant mice by reducing neuroinflammation through
Jian-Da Lin1, Hsun Li2, Chia-Lang Hsu3
1Department of Biochemical Science and Technology, National Taiwan University, Taipei, Taiwan.
Introduction:
Alterations in the gut microbiota accompanied by intestinal inflammation are early features of Parkinson's disease (PD). Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene represent a common genetic risk factor for PD and inflammatory bowel disease. Parabacteroides goldsteinii has been reported to alleviate intestinal and systemic inflammation. However, whether modulation of the gut microenvironment at early disease stage can attenuate PD progression remains unclear.
Objective:
To investigate the impact of P. goldsteinii colonization prior to the onset of motor dysfunction on PD progression.
Methods:
We established a germ-free PD mouse model carrying the LRRK2 G2019S mutation and administered P. goldsteinii orally at the pre-symptomatic stage to evaluate its effects on motor performance and PD-related neuropathology. Spatial and bulk RNA transcriptomic analyses of brain tissue, together with cytokine profiling, were conducted to assess central changes. To investigate gut immunomodulatory mechanisms, we performed intestinal bulk and single-cell RNA sequencing, spectral flow cytometry as well as cellular bioenergetic analyses.
Results:
Germ-free conditions partially alleviated PD-like phenotypes in LRRK2 G2019S mice. Colonization with P. goldsteinii at 5-months of age, prior to motor symptom onset, further improved locomotor performance, reduced neuronal α-synuclein aggregations, and mitigated microglial activation and dopaminergic neurodegeneration. Neuroprotection was mediated through enhanced noncanonical neuronal IL-12 receptor-dependent neurotrophic support without activating the canonical STAT4 phosphorylation pathway, along with suppression of microglial activation and downregulation of LRRK2 kinase activity. At the intestinal level, P. goldsteinii suppressed TLR4-driven inflammation, expanded anti-inflammatory intraepithelial CD4+CD8αα+ T cells, promoted dendritic cell and macrophage differentiation, upregulated epithelial tight-junction genes, and improved mitochondrial bioenergetics in intestinal cells.
Conclusion:
P. goldsteinii colonization attenuates the progression of LRRK2-associated parkinsonism by restoring intestinal homeostasis and reducing neuroinflammation. These findings underscore the therapeutic potential of modulating the gut-immune-brain axis during the prodromal stage of PD.
Insights
Administering Parabacteroides goldsteinii before motor symptoms emerge can slow Parkinson's disease (PD) progression. This gut bacterium restores intestinal balance and reduces neuroinflammation, offering therapeutic potential for early-stage PD.
Area of Science:
- Neuroscience
- Microbiology
- Immunology
Background:
- Parkinson's disease (PD) is linked to gut microbiota alterations and inflammation.
- LRRK2 gene mutations are a significant genetic risk factor for PD and inflammatory bowel disease.
- Parabacteroides goldsteinii shows potential in reducing intestinal and systemic inflammation.
Purpose of the Study:
- To investigate the therapeutic effect of P. goldsteinii colonization on PD progression before motor dysfunction onset.
- To assess the impact of P. goldsteinii on LRRK2-associated parkinsonism in a pre-symptomatic stage.
Main Methods:
- Established a germ-free LRRK2 G2019S-mutant PD mouse model.
- Administered P. goldsteinii orally at the pre-symptomatic stage.
- Utilized transcriptomic, cytokine profiling, RNA sequencing, flow cytometry, and bioenergetic analyses to assess central and intestinal changes.
Main Results:
- P. goldsteinii colonization improved motor performance and reduced neuropathology, including α-synuclein aggregation and dopaminergic neurodegeneration.
- Neuroprotection involved IL-12 receptor signaling, suppressed microglial activation, and reduced LRRK2 kinase activity.
- Intestinal effects included suppressed TLR4 inflammation, expanded CD4+CD8αα+ T cells, improved epithelial barrier function, and enhanced mitochondrial bioenergetics.
Conclusions:
- P. goldsteinii attenuates LRRK2-associated parkinsonism by restoring gut homeostasis and reducing neuroinflammation.
- Modulating the gut-immune-brain axis via P. goldsteinii shows therapeutic promise for prodromal PD.
- Targeting the gut microbiota may offer a novel strategy for early PD intervention.
More Related Videos
12:49Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
Published on: March 21, 2020
08:09Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Related Concept Videos
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Neural Regulation